EWH vs XBI
iShares MSCI Hong Kong ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.50% for EWH.
- • EWH pays a higher dividend yield (4.63%).
Side-by-side metrics
| Metric | EWH | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.50% | 0.35% |
Dividend yield Trailing 12-month yield. | 4.63% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $1.24B | $10.92B |
YTD return | 11.78% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.58 | 1.01 |
P/E ratio | 13.34 | — |
Last price | $23.11 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
EWH top holdings
| 1299.HK | AIA Group Ltd | 23.80% |
| 0388.HK | Hong Kong Exchanges and Clearing Ltd | 14.20% |
| 0001.HK | CK Hutchison Holdings Ltd | 5.59% |
| 2388.HK | BOC Hong Kong Holdings Ltd | 4.64% |
| 0002.HK | CLP Holdings Ltd | 4.48% |
| 0669.HK | Techtronic Industries Co Ltd | 4.43% |
| 0016.HK | Sun Hung Kai Properties Ltd | 4.18% |
| 0823.HK | Link Real Estate Investment Trust | 3.74% |
| 0006.HK | Power Assets Holdings Ltd | 3.24% |
| 0003.HK | Hong Kong and China Gas Co Ltd | 3.01% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About EWH
EWH (iShares MSCI Hong Kong ETF) is Hong Kong large and mid-cap equities. Managed by iShares, the fund carries $1.2B in assets under management, an expense ratio of 0.50%, a dividend yield of 4.63%. Its largest holding is AIA Group Ltd (1299.HK), which represents 23.8% of the portfolio. Real Estate is the fund's largest sector exposure at 18.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.